Clinical Trial Results: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating HPV vaccine PRGN-2009 alone or with anti-PD-L1/TGF-beta trap M7824 in HPV-associated cancers; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Cervical Cancer
• Hpv-associated Cancers
• Oropharyngeal Cancer
• Penile Cancer
• Rectal Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• M7824 (bintrafusp alfa)
• PRGN-2009

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-08-18